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A NEW COMBINED DTP-HBV-
HIB VACCINE- STRATEGY FOR 
INCORPORATION OF HIB 
VACCINATION INTO CHILDHOOD 
IMMUNISATION PROGRAMMES 
A Ra:inkissoon, H M Coovadia, P Jugnundan, P Willems, 
B R Clemens 
Objectives. To evaluate the immunogenicity and reactogenicity 
of a pentavalent vaccine prepared by extemporaneously 
mixing diphtheria-tetanus pertussis-hepatitis B vaccine (DTP-
HBV) and lyophilised Haemophilus injluenzae type B (Hib)-
tetanus conjugate vaccines in the same syringe, compared 
with the same vaccines given as separate, concomitant 
administrations. 
Design. Open, randornised comparative study. 
Setting. Durban, South Africa. 
Subjects. A total of 120 healthy male and female infants were 
enrolled in the trial and randomised into two groups; group 1 
received the combined administration (DTP-HBV-Hib), and 
group 2 received separate administrations of DTP-HBV and 
Hib vaccines. Vaccines were given as a three-dose primary 
vaccination course at 6,10 and 14 weeks of age. 
Outcome measures. Antibody levels were measured using 
standard techniques and local and general solicited 
symptoms were recorded using diary cards. 
Results. All subjects had seroprotective titres against 
diphtheria and tetanus; and antipolyribose-ribitol phosphate 
(PRP) titres ~ 0.15 )lg / ml 1 month after the final dose. A 
vaccine response (defined as post-vaccination titres 
~ 15 ELISA (EL).U/ ml in initially seronegative subjects; and 
as post- vaccination titres ~ pre-vaccination titres in ini tially 
seropositive subjects) against the pertussis component was 
seen in 83% and 85% of subjects in the groups receiving 
combined and separa te administration . No differences were 
Medical Research Council, 296 Umbilo Rd, Durban 
A Ramkissoon, MSc (Mec!Sc), PhD, MBA 
Departmen ts of Paediatrics and Child Health and Family Medicine, University of 
Natal, Durban 
H M Coovadia, BSc Hons, MSc (lmm), FCP, MD, DSc 
P Jugnundan, BSc, Mb ChB, MMedSc (Clin Pharm), MPrax Med, MFGP, 
Dip Mid Cog 
SmithKline Beecham Biologicals, Rue de l'Institut, B-1330 Rixensaart, Belgium 
P Willem s 
B R Clemens 
~ ORIGINAL ARTICLES 
seen in any of the geometric mean titres (GMTs) betwe~n the 
two administrations either 2 months after the second dose or 
1 month after the final dose. There was no observed increase 
in reactogenicity in the group receiving the mixed 
administration. 
Conclusions. The results demonstrate that combined DTP-
HBV-Hib vaccine is well tolerated and immunogenic. 
5 Afr Med I 2001; 91: 864-869. 
Diphtheria, tetanus and pertussis (DTP) vaccinations have been 
the cornerstone of infant vaccination for several decades. It is 
widely accepted that combination vaccines offer the most 
practical and cost-effective means of achieving ever-expanding 
immunisation goals.1 Because DTP vaccination is mandatory in 
most childhood immunisation schedules, high coverage has 
been established. This, therefore, makes DTP a preferred 
combination partner. In recognition of this, the World Health 
Organisation (WHO) has already recommended the 
development of DTP-hepatitis B vaccine (HBV) combinations 
in order to facilitate the incorporation of hepatitis B vaccination 
into the Expanded Programme of Immunisation (EPI),' which 
is now being undertaken.H 
In 1998, the WHO recommended the incorporation of 
Haemophilus influenzae type B (Hib) vaccination into routine 
infant immunisation programmes, as appropriate to national 
capacities and priorities.' The importance of Hib vaccination, 
especially in early childhood, is clear, particularly in developing 
countries where the disease occurs in young children, with 
most cases occurring before 12 months of age, and half of these 
before 6 months of age• In addition infant immunisation has 
alread y reduced the rates of invasive disease in the developed 
world• and recent efficacy trials suggest that this could now be 
achieved in the developing world.'o-" The addition of the Hib 
vaccine to the DTP-HBV combination vaccine would offer a 
means of incorporating Hib into childhood vaccination 
schedules with minimal cost increase and maximum ease. 
Any new vaccine, and in ,_Jarticular combination vaccines, 
must be carefully evaluated in order to ensure that there is no 
loss of immune response to any of the components or any 
increase in reactogenicity. In consideration of these factors, we 
have evaluated the safety and immunogenicity of the 
pentavalent combination, whole-cell pertussis-based DTP 
(DTPw)-HBV-Hib, produced by the extemporaneous mixing of 
DTPw-HBV and Hib when given as a primary course to 
children at 6, 10 and 14 weeks of age. 
MATERIALS AND METHODS 
Study design and participants 
The study was an open, randomised clinical trial and was 
conducted by the University of Natal in Durban, South Africa. 
The study received local ethical approval and was conducted 
according to the Declaration of Helsinki and the Good Clinical 
Practice Guidelines (International Conference on 
Harmonisation, April1996). Before enrolment, written 
informed consent was obtained from the children's parents or 
guardians. 
A total of 120 healthy male and female infants between 6 and 
10 weeks of age were enrolled in the triaL Subjects were 
eligible to participate if they did not violate any of the 
exclusion criteria. These were: participation in another trial; 
immunosuppressive or immunoglobulin therapy; any 
congenital defects, chroni illness, acute condition or systemic 
dysfunction (especially relating to the central nervous system 
(CNS)); history of allergic reaction or immune disorder 
(including evidence of being born to an HIV-seropositive 
mother). In addition, during the trial both contraindications to 
vaccination (encephalopathy and hypersensitivity immediate 
anaphylactic reaction) and reactions (fever ~ 40°C and 
persistent, inconsolable screaming or crying > 3 hours within 
48 hours of vaccination, high-pitched screaming and crying, 
convulsions with or without fever) associated with whole-cell 
Bordetel/a pertussis vaccination according to the Advisory 
Committee on Immunization Practices (ACIP) 
recommendations" were considered as exclusion criteria. 
Vaccines 
Subjects were randomised into two groups. Group 1 received 
DTPw-HBV extemporaneously mixed with Hib in the same 
syringe, and group 2 received the same vaccines as separate, 
concomitant injections. A single, 0.5 ml dose of DTPw-HBV-
Hib vaccine was prepared by resuspending the lyophilised Hib 
vaccine (10 )lg of polyribose-ribitol phosphate (PRP) 
conjugated to- 30 )lg tetanus toxoid, 10 mg lactose) in the 
contents of one vial of DTP-HBV (7.5 limit flocculation (Lf) 
diphtheria toxoid, 3.25 Lf tetanus toxoid, 15 IU whole cell 
pertussis, 10 )lg recombinant hepatitis B surface antigen 
(HbsAg), 0.63 mg aluminium (as aluminium salts), 25 )lg 
thiomersaJ, 150 mM sodium chloride and 0.5 mg 
phenoxyethanol (Tritanrix-HB, SmithKline Beecham Biologicals). 
For separate administration, a 0.5 ml dose of Hib (Hiberix, 
Smithl<line Beecham Biologicals) was prepared by 
reconstituting the lyophilised pellet in saline solution (sodium 
chloride ( aCl) 9 mg/ ml) supplied by the manufacturer. 
Vaccines were administered intramuscularly in the 
anterolateral region of the thigh at 6, 10 and 14 weeks of age. 
Reactions 
Diary cards were used by parents or guardians to record 
solicited local reactions (pain, redness and swelling) and 
general adverse experiences (irri tability, unusual crying, 
drowsiness, feeding problems, diarrhoea and vomiting) on the 
day of vaccination and for 3 subsequent days. Any redness or 
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swelling was measured, a diameter > 20 mm being defined as 
severe. For all other symptoms 'severe' was defined as 
preventing normal daily activities. Parents were requested to 
contact study personnel for further assessment if their child 
experienced any severe or alarming symptom. The outcome of 
all adverse experiences was recorded and the relationship to 
vaccination was assessed. 
Serology 
Sera were taken from infants immediately before the first dose, 
approximately 2 months after the second dose, and 
approximately 1 month after the final dose. Samples were 
stored at- 20°C until analyses were performed at SrnithKline 
Beecham Biologicals in a blinded fashion. Anti-hepatitis B 
surface antigen (HBs) antibodies were determined using a 
commercial radio-immunoassay (AUSAB, Abbott); the assay 
cut-off was 10 IU/rnl. 13 Anti-diphtheria and antitetanus 
antibody titres were measured by enzyme-linked 
immunosorbent assays (ELISAs). Although antidiphtheria and 
anti tetanus titres > 0.01 IU /rnl are generally considered to be 
protective and a good correlation has been shown to exist 
between in vivo neutralisation tests and the ELISA results for 
this;H" correlation may be reduced at antibody titres < 0.1 
IU/rnl. ·A titre of 0.1 IU / rnl by ELISA was, therefore, 
conservatively set as the cut-off. Anti-whole-cell B. pertussis 
antibody titres (anti-B. pertussis) were measured by ELISA 
using an immunoglobulin G (IgG) enzyme immuno-assay 
(EIA) test kit (Labsystem, ICN-FLOW); the assay cut-off was 15 
ELISA (EL).U/rnl. The anti-PRP antibodies were measured 
using a radio-labelled antigen-binding assay; assay cut-off was 
0.15 pg/rnl. 
Seroconversion was defined as titres greater than assay cut-
off. All asay cut-offs were considered to be seroprotective, 
except for B. pertussis for which there is no serological correlate 
of protection. A vaccine response against B. pertussis in initially 
seronegative subjects was defined as the induction of antibody 
titres greater or equal to the assay cut-off value; and in initially 
seropositive subjects as a post-vaccination titre greater than or 
equal to the individual's pre-vaccination titre, thereby taking 
into account the half-life (approximately 40 days) of maternal 
antibodies. •• 
Statistical analysis 
Geometric mean titres (GMTs) were calculated for all 
antibodies (titres below the assay cut-off value were given an 
arbitrary value of one-half ,the assay cut-off). All statistical 
analyses were performed using SAS with a type 1 error of 5%. 
Fisher's exact test was used to compare seroconversion rates 
and the confidence interval was used to compare GMTs 
between groups. The two-sided Fisher 's exact test was used to 
determine the incidence of local reactions and general adverse 
reactions between groups. 
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RESULTS 
Overall, the combined administration compared favourably 
with the vaccines given separately. Responses to each 
component in the combined preparation were similar to those 
obtained when the administration was separate (Table I). All 
subjects in both groups had antibody titres above the assay cut-
off threshold 1 month after the final dose (Table I). Indeed, the 
percentage of subjects with protective titres for all vaccine 
components in both groups was extremely high (Table I). 
Tab le I. Seroconversion rates post second and third dose 
Group 1 (combined) · Group 1 (separate) 
DTP-HBV-Hib (N = 49) DTP-HBV+Hib (N = 48) 
p 11* p 111t P11* P111t 
Anti-HBs 89.6 100 91.7 100 
Antidiphtheria 91.7 100 91.7 100 
Anti tetanus 97.3 100 93.8 100 
Anti pertussis 83.0 100 85.4 100 
Anti-PRP 97.9 100 97.9 100 
ComparisOn of Pll seroconversion rates between groups: anti-HBs (P = 1.00); anti-
diphtheria (P = 1.00); anti tetanus (P = 0.62); antipertussis (P = 0.67); anti-PRP (P = 1.00). 
'Pll = 2 months after the second dose. 
tPlll = 1 month after the third dose. 
The GMTs for each component in either group are illustrated 
in Fig. 1, A-E. o differences were detected in the GMTs after 
the second and third dose of the vaccines in both groups, 
except for a significantly higher anti tetanus antibody titre after 
the second dose in the combined group. The latter occurrence 
may be ascribed to chance as no plausible explanation exists for 
why this may have occurred. A month after the final dose, this 
difference had disappeared. 
Table II provides data on safety; it is clear that there are no 
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Fig. lA. Anti-HBs GMTs post second and third dose (vertical bars 
represent standard error (SE)). 
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Fig. 18. Anti-diphtheria GMTs post second and third dose (vertical 








Pll (mo. 6) Pill (mo. 7) 
Fig. 1C. Anti-tetanus GMTs post second and third dose (vertical bars 
represent standard error (5£)). 
generalised adverse effects. Although fever is a common 
reaction, quantitative measurement of fever is not common 
practice on the part of parents and guardians. To ensure 
protocol compliance, therefore, quantitative measurements 
were restricted to further assessments by study personnel 
when consulted by parents. One child suffered an afebrile 
convulsion. She was not hopitalised, but 6 days later 
underwent a computed tomography (CT) scan which was 
normal and she was said to be clinically well. We judged the 
episode to be 'possibly related' 1o vaccination. Subsequent 
follow-up revealed normal development with no sequelae. 
Only one other serious event was reported during the trial 
which was not considered to be related to vaccination, and no 
drop-out was due to a vaccine-related event. The majority of 
drop-outs (7 subjects) occurred as a result of subjects having 
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Fig. 10. Anti-pertussis GMTs post second and third dose (vertical 
bars represent standard error ( 5 E)). 











Pll(mo.6) Plll (mo. 7) 
Fig. 1 E. Anti-PRP GMTs post second and third dose (vertical bars 
represent standard error (5£)). 
a severe episode of influenza (unrelated to vaccination). ln 
addition, three parents did not want blood to be taken from 
their children and therefore withdrew their consent. 
DISCUSSION 
The benefits of combination vaccines are evident, the most 
apparent being the decreased discomfort to the child and 
simplified administrative and delivery logistics. There is, 
owever, one concern that has been raised during recent years, 
viz. the lower apparent immune response to some components, 
as manifested by lower antibody titres. 17•18 
Generally such effects are small and inconsistent and it has, 
therefore, been difficult to attach any clinical significance to 
such observations' 7•18 Furthermore, these observations are more 
common with acellular pertussis (DTPa)-based vaccines than 
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Table II. Incidence of solicited local reactions and general adverse reactions 
Group 1 (N =172)* Group 2 (N = 168)* 
DTP-HBV-Hib DTP-HBV Hib 
(right thigh) (right thigh) (left thigh) 
Local symptoms Total % (N)t Total % (N)t Total % (N/ 
Pain 43.6 (75) 37.5 (63) 32.1 (54) 
Severe 8.7 (15) 8.3 (14) 5.4 (9) 
Redness 32.0 (55) 33.3 (56) 22.6 (38) 
>20mm 2.3 (4) 3.0 (5) 0.6 (1) 
Swelling 45.3 (78) 39.3 (66) 22.6 (38) 
>20mm 8.1 (14) 6.0 (10) 2.4 (4) 
General symptoms DTP-HBV-Hib DTP-HBV+Hib 
Diarrhoea 5.2 (9) 2.4 (4) 
Severe 1.7 (3) 0.6 (1) 
Related 0.0 (0) 0.0 (0) 
Drowsiness 9.9 (17) 11.9 (20) 
Severe 1.2 (2) 0.6 (1) 
Related 0.0 (0) 0.0 (0) 
Feeding problems 17.4 (30) 12.5 (21) 
Severe 2.9 (5) 3.5 (6) 
Related 0.0 (0) 0.0 (0) 
Irritability 27.3 (47) 31.0 (52) 
Severe 5.8 (10) 8.9 (15) 
Related 0.5 (1) 0.0 (0) 
Unusual crying 33.1 (57) 32.1 (54) 
Severe 13.9 12.5 (21) 
Related 1.2 (2) 0.0 (0) 
Vomiting 5.8 (10) 5.4 (9) 
Severe 0.6 (1) 0.6 (1) 
Related 0.0 (0) 0.0 (0) 
Comparison of the incidence of symptoms between groups: pain (P = 0.27); redness (P = 0.82); swelling (P = 0.27); diarrhoea (P = 0.26); drowsiness (P = 0.60); feeding problems (P = 0.23); 
irritability (P = 0.48); unusual crymg (P = 91); vonuting (P = 1.00). 
There was no statistical difference in the comparison of any other individual symptom between groups. 
•N = number of doses given. 
N - number of doses reported for a given symptom. 
with DTPw vaccines.17•19•20 This may be due, in part, to the 
adjuvant effect of the whole-cell pertussis component." In this 
study we saw no diminished response to any component in 
the combined administration group (group I) compared with 
group 2. All subjects in both groups had titres above the assay 
cut-offs 1 month after the final dose, as shown in Table I. With 
regard to the antidiphtheria, antitetanus, anti-HBs and anti-
PRP responses, these values are considered to be indicative of 
protection. Notable then, is the high percentage of subjects in 
whom protective titres had been achieved 2 months after the 
second dose. This may be of benefit, especially in developing 
countries where travel to health centres is not always easy and 
therefore full compliance is not always achieved. In addition, 
no differences in post-second or third dose GMTs were seen 
between groups, with the exception of the anti tetanus GMTs 
post-second dose (Fig. 1, A-E). The post-second dose anti-
tetanus GMTs were significantly higher in the group receiving 
the combined administration; however, there was no difference 
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between the groups 1 month after the final dose. 
In this trial the anti-PRP response following separate 
administration of monovalent Hib was compared with the 
response seen following the DTP-HBV-Hib combination. This 
design would then be the most likely to elucidate an effect due 
to combination if it existed. The findings here show that the 
combination had no effect on either the seroconversion rates (at 
0.15 !lg / ml or 1.0 !lg/ ml - data not shown), or the post-
vaccination GMTs (post second or third dose). This 
observation confirms the results of an earlier trial where the 
same vaccines were used.21 
This study also assessed the comparative safety of the two 
vaccine administrations (data shown in Table II). There was no 
difference in the incidence of any symptom between the two 
groups. Furthermore, the incidence of symptoms was similar 
to those reported for DTPw vaccines,23 and in addition there 
was a low number of severe reactions (maximum incidence 
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was 8.9% for severe irritability). The whole-cell pertussis 
~omponent is responsible for the majority of reactions 
following DTPw vaccination,23 and in the past has been 
'lSSociated with a number of serious adverse events." 'Unusual 
~rying' has been described as a common occurrence following 
.vhole-cell vaccination. Although the incidence of unusual 
:rying was 33.1% and 32.7% in groups 1 and 2 respectively, 
Jnly an incidence of 1.2% and 0% respectively were considered 
to be related to vaccination on the basis of further questioning 
Jf the parents regarding any association of the crying episode 
:o nonspecific events such as hunger, teething, etc. This was 
·Jecause we felt that parents were not strictly adhering to the 
i efinition of unusual crying." 
The results of this trial show that the novel pentavalent 
vaccine, DTP-HBV-Hib, is well tolerated and immunogenic and 
:he addition of Hib does not adversely affect the reactogenicity 
Jr the immunogenic profile. Having demonstrated the clinical 
·easibility, it is worth reiterating the economic and logistical 
1dvantages. The cost-benefits of monovalent Hib vaccination, 
'n terms of the savings associated with treatment costs, have 
1lready been demonstrated.".n This, coupled with cost savings 
that can be made by combining the Hib vaccine with DTP-
I.JBV, lends further support to the use of the combined vaccine 
m d constitutes an attractive option to health care providers. 
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